Gene therapy approval in ultra-rare immune deficiency

Rocket Pharmaceuticals won FDA approval for Kresladi, a gene therapy for leukocyte-adhesion deficiency type 1 (LAD1), an inherited immunodeficiency that can be fatal in infancy. The company positioned the approval as both the first gene therapy for this ultra-rare disease and its first commercial product.